Skip to content

Prediction Model for MINS After Major Hepatobiliary Surgery

Development of an Interpretable Prediction Model for Myocardial Injury After Noncardiac Surgery in Patients Undergoing Major Hepatobiliary Surgery

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07335042
Enrollment
1800
Registered
2026-01-12
Start date
2026-01-14
Completion date
2027-06-30
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatobiliary Diseases, Liver Neoplasm, Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications

Keywords

MINS, Major Hepatobiliary Surgery, Hepatectomy, Hepatic Inflow Occlusion, Pringle Maneuver, Prediction Model, High-sensitivity Cardiac Troponin

Brief summary

This multi-center, prospective observational study aims to develop and validate an interpretable prediction model for Myocardial Injury After Noncardiac Surgery (MINS) in patients undergoing major hepatobiliary surgery. The study adopts a nested modeling strategy, starting with baseline risk factors (e.g., RCRI) and stepwise incorporating hepatic inflow occlusion strategies (specifically comparing SPVO vs. Pringle maneuver) and routine intraoperative biomarkers. The model's performance will be evaluated using AUC, Net Reclassification Improvement (NRI), and Decision Curve Analysis (DCA), followed by interpretability analysis using SHAP values and external validation in an independent cohort.

Detailed description

Study Design and Methodology: The study consists of four consecutive phases aimed at constructing a robust and interpretable prediction model for MINS. 1. Multi-center Cohort Standardization: Based on clinical data from multiple participating centers, the investigators will establish a standardized structural dataset. Strict inclusion and exclusion criteria will be applied. The process involves rigorous data cleaning and normalization to harmonize demographics, surgical operation details, and perioperative hemodynamic parameters across different centers, laying the foundation for model construction. 2. Nested Modeling and Performance Evaluation: A nested modeling strategy will be employed to assess the incremental predictive value of specific surgical and biological variables: Model A (Baseline): Constructed using standard baseline variables such as the Revised Cardiac Risk Index (RCRI). Model B (+Surgical Technique): Incorporates hepatic inflow occlusion strategies, specifically comparing SPVO (Selective Pringle Vascular Occlusion) vs. Pringle maneuver, along with occlusion duration and frequency. Model C (Full Model): Further incorporates MINS-related biomarkers. Model performance will be comprehensively evaluated using: Discrimination: Area Under the Receiver Operating Characteristic Curve (AUC). Calibration: Calibration plots. Clinical Utility: Net Reclassification Improvement (NRI) and Decision Curve Analysis (DCA) to assess the improvement in risk stratification and clinical net benefit after adding new variables. 3. Model Interpretability Analysis: To enhance the transparency of the model ("White-box" approach), SHAP (SHapley Additive exPlanations) values or similar methods will be utilized. This will quantify and visualize the specific contribution (weight) of key variables, such as SPVO usage, to the individual risk prediction, aligning the statistical results with clinical medical reasoning. 4. External Validation: The final model will undergo validation using an independent external clinical cohort. This step aims to test the stability and generalizability of the model across different center data, defining its applicable scope in real-world clinical scenarios.

Interventions

PROCEDUREMajor Hepatobiliary Surgery

Patients undergo standard major hepatobiliary surgery (e.g., hepatectomy). The specific surgical strategy, including the method of hepatic inflow occlusion (e.g., Pringle maneuver or SPVO), is determined by the attending surgeon based on routine clinical practice and patient condition, not by the study protocol.

Sponsors

Beijing Tsinghua Chang Gung Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Adults (18-85 yr, ASA physical status II-III) undergoing major hepatobiliary surgery were enrolled. Major surgery was defined as duration ≥ 3 h involving hepatectomy (≥ 3 segments) or biliary reconstruction necessitating ICU admission. Eligibility required paired perioperative high-sensitivity cardiac troponin T (hs-cTnT) data and comprehensive documentation of surgical covariates, including surgical approach (laparoscopic vs. open), resection nature (anatomic vs. non-anatomic), number of resected segments, tumor characteristics (size and location), and presence of cirrhosis.

Exclusion criteria

(1) preoperative acute myocardial infarction, unstable angina, heart failure, or chronic kidney disease (estimated glomerular filtration rate \< 60 ml/ (min · 1.73 m2); (2) undocumented inflow occlusion strategy; or (3) non-imputable missing covariates.

Design outcomes

Primary

MeasureTime frameDescription
The area under the receiver operating characteristic curve (AUC) of predictive modelWithin 3 days after surgeryThe area under the receiver operating characteristic curve (AUC) for predicting myocardial injury after noncardiac surgery (MINS) in patients undergoing major hepatobiliary surgery

Secondary

MeasureTime frameDescription
Model calibrationWithin 3 days after surgeryassessed by calibration curve / Hosmer-Lemeshow test
Decision curve analysis (DCA)-derived clinical net benefitWithin 3 days after surgery
Model stability and generalizability in the external validation cohortWithin 3 days after surgeries
Contribution weight of key variables (SPVO, biomarkers) analyzed via SHAPWithin 3 days after surgeires

Countries

China

Contacts

CONTACTZhifeng Gao, MD
gzfa02461@btch.edu.cn+86-15801249466
PRINCIPAL_INVESTIGATORZhifeng Gao, MD

Beijing Tsinghua Changgeng Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026